يعرض 1 - 4 نتائج من 4 نتيجة بحث عن '"Kang-Fortner, Q."', وقت الاستعلام: 0.89s تنقيح النتائج
  1. 1
    دورية أكاديمية
    PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)

    المؤلفون: DeZern, A., Marconi, G., Deeren, D., Diez Campelo, M., Lübbert, M., Krishnamurthy, P., Nagy, Z., Basak, G., Jonášová, A., Morozova, E., Geissler, K., Ofran, Y., Kelley, H., Volkert, A., Baker, K., Kang-Fortner, Q., Hodgson, G., Madigan, C., Roth, D. A., Kelly, M., Fenaux, P.

    المصدر: HemaSphere ; volume 6, page 1800-1801 ; ISSN 2572-9241

    الإتاحة: https://doi.org/10.1097/01.hs9.0000850536.85159.f8Test

    View record in BASE

    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    P492: TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1)

    المؤلفون: Stein, E., de Botton, S., Pigneux, A., McMahon, C., Ball, B., Borthakur, G., Eghtedar, A., Kambhampati, S., Tache, J., Wang, E., Kelley, H., Volkert, A., Baker, K., Kang-Fortner, Q., Hodgson, G., Madigan, C., Warlick, E., Roth, D., Kelly, M., Pollyea, D.

    المصدر: HemaSphere ; volume 6, page 391-392 ; ISSN 2572-9241

    الإتاحة: https://doi.org/10.1097/01.hs9.0000844856.73683.5fTest

    View record in BASE

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors

    المؤلفون: Papadopoulos, K., Sharma, M., Hamilton, E., Richardson, D., Bashir, B., Hodgson, G., Ke, N., Kang-Fortner, Q., Zhou, L., Zamboni, W., Jolin, H., Madigan, C., Kelly, M., Roth, D.

    المصدر: European Journal of Cancer ; volume 138, page S50 ; ISSN 0959-8049

    مصطلحات موضوعية: Cancer Research, Oncology

    الإتاحة: https://doi.org/10.1016/s0959-8049Test(20)31211-9
    https://api.elsevier.com/content/article/PII:S0959804920312119?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0959804920312119?httpAccept=text/plainTest

    View record in BASE

    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    180 Poster - Early evidence of dose-dependent pharmacodynamic activity following treatment with SY-5609, a highly selective and potent oral CDK7 inhibitor, in patients with advanced solid tumors.

    المؤلفون: Papadopoulos, K.1 (AUTHOR), Sharma, M.2 (AUTHOR), Hamilton, E.3 (AUTHOR), Richardson, D.4 (AUTHOR), Bashir, B.5 (AUTHOR), Hodgson, G.6 (AUTHOR), Ke, N.6 (AUTHOR), Kang-Fortner, Q.6 (AUTHOR), Zhou, L.6 (AUTHOR), Zamboni, W.6 (AUTHOR), Jolin, H.6 (AUTHOR), Madigan, C.6 (AUTHOR), Kelly, M.6 (AUTHOR), Roth, D.6 (AUTHOR)

    المصدر: European Journal of Cancer. 2020 Supplement 2, Vol. 138, pS50-S50. 1p.

    مصطلحات موضوعية: *THERAPEUTIC use of antineoplastic agents, *CONFERENCES & conventions, *TRANSFERASES, *TUMORS


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث